<DOC>
	<DOCNO>NCT00260728</DOCNO>
	<brief_summary>The Boston Scientific ACCESS trial seek study safety evaluate success Fusion™ Vascular Access Graft patient need early vascular access hemodialysis .</brief_summary>
	<brief_title>The Boston Scientific ACCESS Trial</brief_title>
	<detailed_description>The Boston Scientific ACCESS trial seek study safety evaluate success Fusion™ Vascular Access Graft patient need early vascular access hemodialysis . The primary objective demonstrate secondary patency 6 month Fusion™ Vascular Access Graft less objective performance criterion ( OPC ) minus clinically relevant margin ( δ ) . The OPC represent secondary patency 6 month standard care access graft . The secondary safety endpoint occurrence CEC-adjudicated device procedure related adverse event 24 month post implant procedure , discharge patient unsuccessful device implantation . Secondary efficacy endpoint include : primary patency ; primary assist patency ; ability revise fail graft ; early access capability ; time hemostasis . Subjects undergo thorough medical assessment physical examination pre-procedure assess peri-procedure . Enrolled subject device implant evaluated 1 , 6 , 12 , 18 24 month post implant procedure .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Need early dialysis access ( ≤72 hour implantation ) : Initiation maintenance dialysis recommend per K/DOQI institutional guideline ; Patient currently receive dialysis via catheter 2 . No prior implantation synthetic graft arm treat 3 . Life expectancy least 2 year , base physician 's assessment medical condition 1 . Patient young 18 year age 2 . Any stenosis vein proximal ( downstream ) implant site , determine previously current ultrasound 3 . Pregnancy 4 . Bleeding disorder , e.g. , low platelet count ( &lt; 50,000 ) , hypercoagulable state , e.g. , antithrombin III deficiency ; antiphospholipid anticardiolipin antibody ; Factor V Leiden ; circulate Lupus anticoagulant ; current , active heparininduced thrombocytopenia ; Protein C S deficiency ; history recurrent deep vein thrombosis relate AV access . 5 . Active malignancy , e.g. , condition either treat consider untreatable 6 . Active systemic infection , e.g. , condition either treat consider untreatable 7 . Uncontrolled major symptomatic medical problem , e.g. , undiagnosed severe pain , metabolic disturbance , fever , etc . 8 . Likelihood poor compliance require dialysis protocol , e.g. , history poor attendance require clinic session noncompliance medication 9 . Mental incapacity ; inability understand treatment instruction 10 . Currently participate another investigational drug device study clinically interfere endpoint study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>vascular access</keyword>
	<keyword>hemodialysis</keyword>
</DOC>